Navigation Links
deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
Date:7/30/2008

0 schizophrenics and 33,000 control subjects. The deletions on chromosomes 1q21, 15q11 and 15q13 were suggestively associated with schizophrenia in this first phase, and then validated in 3,300 cases and 8,000 controls. The SGENE consortium is comprised of deCODE genetics, the National-University Hospital in Reykjavik, the University of Aberdeen, the Ravenscraig Hospital in Greenock, the Institute of Psychiatry at King's College London, the National Public Health Institute in Helsinki, the Ludwig Maximilians University and GlaxoSmithKline's Genetic Research Center in Munich. The SGENE affiliated groups taking part in the second phase of the project were the University of Copenhagen, the University of Oslo, the University of Heidelberg, the University of Bonn, the University Medical Center of Utrecht, Nijmegen Medical Center, the University of Verona, the Duke University Center for Population Genomics and Pharmacogenetics and the University of Sichuan, China.

deCODE and the SGENE consortium gratefully acknowledge the participation in this study of the thousands of patients, family members and control subjects from these eleven countries. This study was supported by the European Union through the SGENE consortium (http://www.SGENE.eu), by grants LSHM-CT-2006-037761 and PIAP-GA-2008-218251.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including de
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
2. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
3. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
4. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
5. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
6. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
10. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
11. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... - Bentley,Pharmaceuticals, Inc. (NYSE: BNT), a specialty ... abstract sponsored by,the Company has been accepted ... Association 67th Scientific Sessions in Chicago.,The abstract, ... Comparison Study of Intranasal Insulin Spray,(Nasulin(TM)) and ...
... Among Patients with,Active Disease, MOUNTAIN VIEW, ... Inc., a clinical-stage biopharmaceutical company,focused on ... target the chemokine system,presented data today ... trial of,Traficet-EN (CCX282-B), an orally-active anti-inflammatory ...
Cached Medicine Technology:Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5
(Date:7/10/2014)... The Capital Institute for Neurosciences at Capital Health ... a clinical trial that delivers chemotherapy to brain tumors ... the procedure, done at Capital Health Medical Center – ... tiny catheter through the patient’s femoral artery in the ... the brain. Once the catheter reached the brain, chemotherapy ...
(Date:7/10/2014)... Colorado (PRWEB) July 10, 2014 ... will gather in Copenhagen this July 13-17 to ... bringing the world closer to breakthroughs in dementia ... the world’s largest conference of its kind. , ... AAIC serves as a catalyst for generating new ...
(Date:7/10/2014)... 10, 2014 In his latest blog ... drug treatment facility CEO Per Wickstrom has listed 5 ... trying to confirm an appointment, get information or sometimes ... following-up without being annoying is a skill that most ... a way to keep the dialogue moving without coming ...
(Date:7/10/2014)... (July 8, 2014) A new study from Colorado ... improvements, poor oral health remains a major problem in ... "The oral health among Native Americans is abysmal with ... of the country," said Terrence Batliner, DDS, MBA, associate ... at the School of Public Health. "The number one ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Teens who ... are more likely to develop emotional symptoms such as ... factors such as these that may exacerbate issues teens ... appropriate treatment and in making decisions about when to ... school for these athletes," study authors Lisa Koehl and ...
Breaking Medicine News(10 mins):Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Some Teens May Face Emotional Problems After Concussion 2
... 26 Velos, Inc., the recognized leader and ... and Net.Orange, Inc., the respected healthcare Internet solutions ... Cancer Research Centers (Mary Crowley). The two companies ... for strong central clinical research infrastructure and implementation ...
... Sandals(R) Originals2 Footwear by BeechHUNTINGTON BEACH, Calif., Feb. ... Yoga Sandals(R) Originals line with new adjustable ... This patented foot therapy can now be customized ... foot , increasing flexibility and helping improve balance ...
... LLC ( http://www.GlenwoodSystems.com ) launches the GlaceComplete product suite which seamlessly ... an assisted medical billing process. The product has been designed ... maximizing revenue contribution for the average office based medical practice. ... ...
... Today, AmeriGlide announced the recipient of this years AmeriGlide Achiever Scholarship. ... a wheelchair. , ... Raleigh, NC (PRWEB) February 26, ... of the first semi-annual AmeriGlide Achiever Scholarship. The AmeriGlide Achiever Scholarship ...
... Honored for Comebacks from Ostomy SurgeryWASHINGTON, Feb. 25 ... improving the lives of other ostomates, was named this ... pilot Robert (Bob) Cuyler was named the first recipient ... ceremony here this evening. Founded in 1984 by ...
... ArvinMeritor (NYSE: ARM ) today announced that ... by Lin Cummins, senior vice president of Communications for ArvinMeritor, ... one of the most challenging economic times in history, I ... and individuals to help wipe out heart disease, the number ...
Cached Medicine News:Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 2Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 3Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 4Health News:Sandal Evolution(R) Takes a Healthy Step 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:AmeriGlide Announces Recipient of AmeriGlide Achiever Scholarship 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 3Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 4Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 5Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 6Health News:ArvinMeritor Proud to Sponsor American Heart Association Campaign 2
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Medicine Products: